1. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases 
Bella Ungar, Idan Levy, Yarden Yavne, Miri Yavzori, Orit Picard, Ella Fudim, Ronen Loebstein, Yehuda Chowers, Rami Eliakim, Uri Kopylov, Shomron Ben-Horin 
Clinical Gastroenterology and Hepatology 
Volume 14, Issue 4, Pages e2 (April 2016)
DOI: /j.cgh
Copyright © 2016 AGA Institute Terms and Conditions

2. Figure 1
(A) Infliximab trough levels in patients with MH versus those with endoscopically active disease (no MH). (B) ROC analysis, correlation between infliximab levels and MH. AUC, area under the curve.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

3. Figure 2
The correlation between ATI levels and MH among patients with satisfactory infliximab levels.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

4. Figure 3
(A) Adalimumab trough levels in patients with MH versus those with endoscopically active disease (no MH). (B) ROC analysis, correlation between adalimumab levels and MH. AUC, area under the curve.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

5. Figure 4 Incremental gain in MH rates in relation to drug serum level.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions

6. Supplementary Figure 1
Drug level in relation to endoscopic score in 2 patients with CD. SES for CD score <3 signifies MH (dashed line). Squares, infliximab therapy patient; circles, adalimumab therapy patient; SES, Simple Endoscopic Score.
Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh )
Copyright © 2016 AGA Institute Terms and Conditions